Clinical trial · Observational
Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure
Utilisation du ZArzio® en Post-Autogreffe de Cellules Souches périphériques Des Patients Atteints de Lymphome ou Myélome (in French)
NCT03323541CI-TRIAL-00034996ZAPAcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
There are limited data concerning the use of biosimilars of filgrastim in autologous stem cell transplantation (ASCT). This study aimed to evaluate G-CSF efficiency and safety (based on haemograms, transfusion needs and complications) of two biosimilars (Zarzio and Ratiograstim®) compared to those of Neupogen® for our patients who underwent ASCT.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Non-hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Filgrastim Prefilled Syringe [Zarzio®] | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Group of patients treated with Zarxio
- description
- All consecutive patients, treated for lymphoma or myeloma, which underwent autologous stem cell transplantation in the University Hospital of Brest. All these patients were treated with biosimilars of Filgrastim: Zarzio®.
- interventionNames
- Drug: Filgrastim Prefilled Syringe [Zarzio®]
Primary outcomes (1)
- measure
- time to bone marrow recovery
- timeFrame
- daily evaluation, around 8 days normally
- description
- timing in days from the day of ASCT until the day when neutrophils \>1 giga/l
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients with DLBCL or multiple myeloma * patients who underwent ASCT in our hospital * patients treated by Zarzio® in post-ASCT phase to accelerate the bone marrow recovery Exclusion Criteria: * patients who underwent ASCT but for other diseases * patients who underwent ASCT for the required diseases but treated with an other biosimilar of Filgrastim * patients who did not sign the informed consent
References
Publications (1)
- RESULTNicol C, Henry C, Couturier MA, Delepine P, Tripogney C, Buors C, Guillerm G, Berthou C, Tempescul A, Ianotto JC. Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only. Leuk Lymphoma. 2017 Sep;58(9):1-3. doi: 10.1080/10428194.2017.1285025. Epub 2017 Feb 7. No abstract available. PMID 28278727